SCHEMBL140749

SCHEMBL140749

Cc1ncc(CO)c(COP(=O)(O)O)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.61
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
HSD17B10 Q99714 1/20 0.61
ESR1 P03372 1/20 0.60
PTGS1 P23219 1/20 0.60
ACP1 P24666 1/20 0.60
PDE4A P27815 1/20 0.60
P2RX1 P51575 1/20 0.60
P2RX2 Q9UBL9 1/20 0.60
PNPO Q9NVS9 1/20 0.59
LMNA P02545 3/20 0.56
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
AOX1 Q06278 1/20 0.48
TRIM24 O15164 1/20 0.47
TRIM33 Q9UPN9 1/20 0.47
PDXK O00764 1/20 0.44
GAA P10253 1/20 0.43
SGPL1 O95470 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29040292 0.99 HPGD (0.59) HPGDKDM4EALDH1A1HSD17B10ESR1
SCHEMBL8967900 0.91 HPGD (0.61) HPGDKDM4EALDH1A1HSD17B10ESR1
SCHEMBL31536462 0.89 HPGD (0.55) HPGDKDM4EALDH1A1HSD17B10ESR1
SCHEMBL1005970 0.89 HPGD (0.58) HPGDKDM4EALDH1A1HSD17B10ESR1
SCHEMBL43880 0.88 ESR1 (0.64) HPGDKDM4EALDH1A1HSD17B10ESR1
SCHEMBL29384180 0.88 ESR1 (0.64) HPGDKDM4EALDH1A1HSD17B10ESR1
Ammonia Solution, Strong SCHEMBL31241292 0.87 ESR1 (0.63) HPGDKDM4EALDH1A1HSD17B10ESR1
Hydrochloric Acid SCHEMBL14331173 0.87 ESR1 (0.63) HPGDKDM4EALDH1A1HSD17B10ESR1
Water SCHEMBL371432 0.87 ESR1 (0.63) HPGDKDM4EALDH1A1HSD17B10ESR1
SCHEMBL15342850 0.86 KDM4E (0.58) HPGDKDM4EALDH1A1HSD17B10ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421264-B2 Compounds and methods for the treatment of pathogenic Neisseria INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2025-09-23 US claimed
EP-4320094-A1 NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF Cosmas Therapeutics Development Inc. (CA) 2024-02-14 EP claimed
WO-2022213195-A1 NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF COSMAS THERAPEUTICS DEVELOPMENT INC. (CA) 2022-10-13 WO claimed
US-20220089626-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PATHOGENIC NEISSERIA INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2022-03-24 US claimed
US-10655153-B2 Chemoenzymatic synthesis of peptide beta-lactones and beta-hydroxy acids WASHINGTON UNIVERSITY (US) 2020-05-19 US claimed
WO-2020051701-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PATHOGENIC NEISSERIA INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2020-03-19 WO claimed
WO-2019169478-A1 TREATMENT OF PROTEIN AGGREGATION DISEASES USING N,N,N-TRIMETHYLCHITOSAN OVENSA INC. (CA) 2019-09-12 WO claimed
US-20180265905-A1 CHEMOENZYMATIC SYNTHESIS OF PEPTIDE BETA-LACTONES AND BETA-HYDROXY ACIDS WASHINGTON UNIVERSITY (US) 2018-09-20 US claimed
EP-3302059-A1 SELECTIVE SOLVENT FREE PHOSPHORYLATION Chromadex, Inc. (US) 2018-04-11 EP claimed
WO-2016196941-A1 SELECTIVE SOLVENT FREE PHOSPHORYLATION CHROMADEX, INC. (US) 2016-12-08 WO claimed
US-20070292541-A1 Method for Producing Organically-Bound Vitamin B JHS-PRIVATSTIFTUNG (AT) 2007-12-20 US claimed
EP-1867728-A1 Process for the preparation of a plant enriched with B vitamins JHS-Privatstiftung (AT) 2007-12-19 EP claimed
EP-0525821-B1 Methods and structures employing non-radioactive chemically-labeled polynucleotide probes ENZO BIOCHEM INC (US) 2006-03-29 EP claimed
EP-1009416-A1 WEIGHT CONTROL COMPOSITION COMPRISING HYPERICUM PERFORATUM Braswell, A., Glenn (US) 2000-06-21 EP claimed
US-5911992-A Method for controlling weight with hypericum perforatum and garcinia cambogia A. GLENN BRASWELL (US) 1999-06-15 US claimed
WO-1998056397-A1 WEIGHT CONTROL COMPOSITION COMPRISING HYPERICUM PERFORATUM BRASWELL A GLENN (US) 1998-12-17 WO claimed
EP-0495270-B1 Azaribine composition DRELL WILLIAM DR (US) 1996-01-03 EP claimed
EP-0338916-B1 HAEMOGLOBIN MACROMOLECULAR COMPLEXES, METHOD OF PREPARATION AND THEIR USES PASTEUR MERIEUX SERUMS ET VACCINS (FR) 1992-07-01 EP claimed
US-4921809-A Polymer coated solid matrices and use in immunoassays FINDLEY ADHESIVES, INC. (US) 1990-05-01 US claimed
EP-0312135-A2 Polymer coated solid matrices and use in immunoassays FINDLEY ADHESIVES INC. (US) 1989-04-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089626-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PATHOGENIC NEISSERIA NMBR, MLEC, BPGM HPGD 864/4885KDM4E 1724/4885ALDH1A1 2797/4885
US-12421264-B2 Compounds and methods for the treatment of pathogenic Neisseria NMBR, MLEC, BPGM HPGD 864/4885KDM4E 1724/4885ALDH1A1 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.